{
    "balance": {
        "data": [
            "CONSOLIDATED BALANCE SHEETS\t(unaudited)\t(in millions, except per share amounts)\tMarch 31, 2023\tDecember 31, 2022\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t4,936\t$\t5,412\tShort-term marketable debt securities\t936\t973\tAccounts receivable, net\t4,162\t4,777\tInventories\t1,576\t1,507\tPrepaid and other current assets\t1,846\t1,774\tTotal current assets\t13,456\t14,443\tProperty, plant and equipment, net\t5,479\t5,475\tLong-term marketable debt securities\t1,327\t1,245\tIntangible assets, net\t28,348\t28,894\tGoodwill\t8,314\t8,314\tOther long-term assets\t4,952\t4,800\tTotal assets\t$\t61,876\t$\t63,171\tLiabilities and Stockholders  Equity\tCurrent liabilities:\tAccounts payable\t$\t627\t$\t905\tAccrued rebates\t3,477\t3,479\tOther current liabilities\t4,140\t4,580\tCurrent portion of long-term debt and other obligations, net\t2,283\t2,273\tTotal current liabilities\t10,528\t11,237\tLong-term debt, net\t22,956\t22,957\tLong-term income taxes payable\t3,775\t3,916\tDeferred tax liability\t2,401\t2,673\tOther long-term obligations\t1,277\t1,179\tCommitments and contingencies (Note 10)\tStockholders  equity:\tPreferred stock, par value $\t0.001\tper share;\t5\tshares authorized;\tno\tne outstanding\t \t \tCommon stock, par value $\t0.001\tper share;\t5,600\tshares authorized;\t1,248\tand\t1,247\tshares issued and outstanding, respectively\t1\t1\tAdditional paid-in capital\t5,793\t5,550\tAccumulated other comprehensive income (loss)\t(\t20\t)\t2\tRetained earnings\t15,223\t15,687\tTotal Gilead stockholders  equity\t20,997\t21,240\tNoncontrolling interest\t(\t58\t)\t(\t31\t)\tTotal stockholders  equity\t20,939\t21,209\tTotal liabilities and stockholders  equity\t$\t61,876\t$\t63,171\tSee accompanying notes.\t3\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS OF INCOME\t(unaudited)\tThree Months Ended\tMarch 31,\t(in millions, except per share amounts)\t2023\t2022\tRevenues:\tProduct sales\t$\t6,306\t$\t6,534\tRoyalty, contract and other revenues\t46\t56\tTotal revenues\t6,352\t6,590\tCosts and expenses:\tCost of goods sold\t1,401\t1,424\tResearch and development expenses\t1,447\t1,178\tAcquired in-process research and development expenses\t481\t8\tIn-process research and development impairment\t \t2,700\tSelling, general and administrative expenses\t1,319\t1,083\tTotal costs and expenses\t4,647\t6,393\tOperating income\t1,705\t197\tInterest expense\t(\t230\t)\t(\t238\t)\tOther income (expense), net\t(\t174\t)\t(\t111\t)\tIncome (loss) before income taxes\t1,300\t(\t152\t)\tIncome tax benefit (expense)\t(\t316\t)\t164\tNet income\t985\t12\tNet loss attributable to noncontrolling interest\t26\t7\tNet income attributable to Gilead\t$\t1,010\t$\t19\tBasic earnings per share attributable to Gilead\t$\t0.81\t$\t0.02\tShares used in basic earnings per share attributable to Gilead calculation\t1,248\t1,255\tDiluted earnings per share attributable to Gilead\t$\t0.80\t$\t0.02\tShares used in diluted earnings per share attributable to Gilead calculation\t1,261\t1,262\tSee accompanying notes.\t4\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME\t(unaudited)\tThree Months Ended\tMarch 31,\t(in millions)\t2023\t2022\tNet income\t$\t985",
            "Consolidated Balance Sheets:\t(in millions)\tMarch 31, 2023\tDecember 31, 2022\tCash and cash equivalents\t$\t63\t$\t75\tShort-term marketable debt securities\t936\t973\tLong-term marketable debt securities\t1,327\t1,245\tTotal\t$\t2,326\t$\t2,293\t13\tThe following table summarizes our available-for-sale debt securities by contractual maturity:\tMarch 31, 2023\t(in millions)\tAmortized Cost\tFair Value\tWithin one year\t$\t1,006\t$\t999\tAfter one year through five years\t1,325\t1,308\tAfter five years through ten years\t14\t14\tAfter ten years\t5\t5\tTotal\t$\t2,350\t$\t2,326\tEquity Securities\tEquity Securities Measured at Fair Value\tThe following table summarizes the classification of our equity securities measured at fair value on a recurring basis, on our Condensed Consolidated Balance Sheets:\t(in millions)\tMarch 31, 2023\tDecember 31, 2022\tCash and cash equivalents\t$\t3,175\t$\t3,831\tPrepaid and other current assets\t(1)\t394\t473\tOther long-term assets\t(1)\t982\t943\tTotal\t$\t4,551\t$\t5,248\t________________________________\t(1)\tPrepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.\tOther Equity Securities\tEquity method investments and other equity investments without readily determinable fair values were $\t333\tmillion\tand $\t423\tmillion as of March 31, 2023 and December 31, 2022, respectively, and were excluded from the table above. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.\tUnrealized Gains and Losses\tNet unrealized losses recognized on equity securities were $\t256\tmillion and $\t96\tmillion for the three months ended March 31, 2023, and 2022, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.\t14\t5.\tDERIVATIVE FINANCIAL INSTRUMENTS\tOur operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to li",
            "Consolidated Balance Sheets:\t(in millions)\tMarch 31, 2023\tDecember 31, 2022\tCash and cash equivalents\t$\t3,175\t$\t3,831\tPrepaid and other current assets\t(1)\t394\t473\tOther long-term assets\t(1)\t982\t943\tTotal\t$\t4,551\t$\t5,248\t________________________________\t(1)\tPrepaid and other current assets and Other long-term assets include our equity method investments in Arcus and Galapagos, respectively, for which we elected and applied the fair value option as we believe it best reflects the underlying economics of these investments. Our investment in Galapagos is classified in Other long-term assets due to certain lock-up provisions in our amended subscription agreement with them, which extend to August 2024.\tOther Equity Securities\tEquity method investments and other equity investments without readily determinable fair values were $\t333\tmillion\tand $\t423\tmillion as of March 31, 2023 and December 31, 2022, respectively, and were excluded from the table above. These amounts were included in Other long-term assets on our Condensed Consolidated Balance Sheets.\tUnrealized Gains and Losses\tNet unrealized losses recognized on equity securities were $\t256\tmillion and $\t96\tmillion for the three months ended March 31, 2023, and 2022, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.\t14\t5.\tDERIVATIVE FINANCIAL INSTRUMENTS\tOur operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.\tThe derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of\t18\tmonths or less.\tWe held fore",
            "Consolidated Balance Sheets.\tUnrealized Gains and Losses\tNet unrealized losses recognized on equity securities were $\t256\tmillion and $\t96\tmillion for the three months ended March 31, 2023, and 2022, respectively, and were included in Other income (expense), net on our Condensed Consolidated Statements of Income.\t14\t5.\tDERIVATIVE FINANCIAL INSTRUMENTS\tOur operations in foreign countries expose us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and various foreign currencies, primarily the Euro. To manage this risk, we hedge a portion of our foreign currency exposures related to outstanding monetary assets and liabilities as well as forecasted product sales using foreign currency exchange forward contracts. In general, the market risk related to these contracts is offset by corresponding gains and losses on the hedged transactions. The credit risk associated with these contracts is driven by changes in interest and currency exchange rates and, as a result, varies over time. By working only with major banks and closely monitoring current market conditions, we seek to limit the risk that counterparties to these contracts may be unable to perform. We also seek to limit our risk of loss by entering into contracts that permit net settlement at maturity. Therefore, our overall risk of loss in the event of a counterparty default is limited to the amount of any unrealized gains on outstanding contracts (i.e., those contracts that have a positive fair value) at the date of default. We do not enter into derivative contracts for trading purposes.\tThe derivative instruments we use to hedge our exposures for certain monetary assets and liabilities that are denominated in a non-functional currency are not designated as hedges. The derivative instruments we use to hedge our exposures for forecasted product sales are designated as cash flow hedges and have maturities of\t18\tmonths or less.\tWe held foreign currency exchange contracts with outstanding notional amounts of $\t2.9\tbillion as of March 31, 2023 and $\t3.0\tbillion as of December 31, 2022.\tWhile all our derivative contracts allow us the right to offset assets and liabilities, we have presented amounts in our Condensed Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:\tMarch 31, 2023\tDerivative Assets\tDerivative Liabilities\t(in millions)\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t$\t30\tOther current liabilities\t$\t35\tForeign currency exchange contracts\tOther long-term assets\t1\tOther long-term obligations\t3\tTotal derivatives designated as hedges\t31\t38\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t1\tOther current liabilities\t11\tTotal derivatives not designated a",
            "Consolidated Balance Sheets on a gross basis. The following table summarizes the classification and fair values of derivative instruments, including the potential effect of offsetting:\tMarch 31, 2023\tDerivative Assets\tDerivative Liabilities\t(in millions)\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t$\t30\tOther current liabilities\t$\t35\tForeign currency exchange contracts\tOther long-term assets\t1\tOther long-term obligations\t3\tTotal derivatives designated as hedges\t31\t38\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t1\tOther current liabilities\t11\tTotal derivatives not designated as hedges\t1\t11\tTotal derivatives presented gross on the Condensed Consolidated Balance Sheets\t$\t32\t$\t49\tGross amounts not offset on the Condensed Consolidated Balance Sheets:\tDerivative financial instruments\t(\t24\t)\t(\t24\t)\tCash collateral received / pledged\t \t \tNet amount (legal offset)\t$\t7\t$\t25\t15\tDecember 31, 2022\tDerivative Assets\tDerivative Liabilities\t(in millions)\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t$\t59\tOther current liabilities\t$\t26\tForeign currency exchange contracts\tOther long-term assets\t1\tOther long-term obligations\t9\tTotal derivatives designated as hedges\t59\t35\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t1\tOther current liabilities\t7\tTotal derivatives not designated as hedges\t1\t7\tTotal derivatives presented gross on the Condensed Consolidated Balance Sheets\t$\t60\t$\t42\tGross amounts not offset on the Condensed Consolidated Balance Sheets:\tDerivative financial instruments\t(\t36\t)\t(\t36\t)\tCash collateral received / pledged\t \t \tNet amount (legal offset)\t$\t25\t$\t7\tThe following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements:\tThree Months Ended\tMarch 31,\t(in millions)\t2023\t2022\tDerivatives designated as hedges:\tNet gain (loss) recognized in Accumulated other comprehensive income\t$\t(\t6\t)\t$\t28\tNet gain reclassified from Accumulated other comprehensive income into Product sales\t$\t24\t$\t22\tDerivatives not designated as hedges:\tNet gain (loss) recognized in Other income (expense), net\t$\t(\t3\t)\t$\t19\tThe majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income (loss) as of March 31, 2023 are expected to be reclassified to Product sales within\t12\tmonths. There were\tno\tdiscontinuances of cash flow hedges for the three months ended March 31, 2023 and 2022.\tThe cash flow effects of our derivative contracts for the three months ended March 31, 2023 and 2022 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.\t6.\tACQUISITIONS, COLLABORATIONS AND OTHER",
            "Consolidated Balance Sheets\t$\t32\t$\t49\tGross amounts not offset on the Condensed Consolidated Balance Sheets:\tDerivative financial instruments\t(\t24\t)\t(\t24\t)\tCash collateral received / pledged\t \t \tNet amount (legal offset)\t$\t7\t$\t25\t15\tDecember 31, 2022\tDerivative Assets\tDerivative Liabilities\t(in millions)\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t$\t59\tOther current liabilities\t$\t26\tForeign currency exchange contracts\tOther long-term assets\t1\tOther long-term obligations\t9\tTotal derivatives designated as hedges\t59\t35\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t1\tOther current liabilities\t7\tTotal derivatives not designated as hedges\t1\t7\tTotal derivatives presented gross on the Condensed Consolidated Balance Sheets\t$\t60\t$\t42\tGross amounts not offset on the Condensed Consolidated Balance Sheets:\tDerivative financial instruments\t(\t36\t)\t(\t36\t)\tCash collateral received / pledged\t \t \tNet amount (legal offset)\t$\t25\t$\t7\tThe following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements:\tThree Months Ended\tMarch 31,\t(in millions)\t2023\t2022\tDerivatives designated as hedges:\tNet gain (loss) recognized in Accumulated other comprehensive income\t$\t(\t6\t)\t$\t28\tNet gain reclassified from Accumulated other comprehensive income into Product sales\t$\t24\t$\t22\tDerivatives not designated as hedges:\tNet gain (loss) recognized in Other income (expense), net\t$\t(\t3\t)\t$\t19\tThe majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income (loss) as of March 31, 2023 are expected to be reclassified to Product sales within\t12\tmonths. There were\tno\tdiscontinuances of cash flow hedges for the three months ended March 31, 2023 and 2022.\tThe cash flow effects of our derivative contracts for the three months ended March 31, 2023 and 2022 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.\t6.\tACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS\tWe enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. The collaborations and other arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arra",
            "Consolidated Balance Sheets:\tDerivative financial instruments\t(\t24\t)\t(\t24\t)\tCash collateral received / pledged\t \t \tNet amount (legal offset)\t$\t7\t$\t25\t15\tDecember 31, 2022\tDerivative Assets\tDerivative Liabilities\t(in millions)\tClassification\tFair Value\tClassification\tFair Value\tDerivatives designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t$\t59\tOther current liabilities\t$\t26\tForeign currency exchange contracts\tOther long-term assets\t1\tOther long-term obligations\t9\tTotal derivatives designated as hedges\t59\t35\tDerivatives not designated as hedges:\tForeign currency exchange contracts\tPrepaid and other current assets\t1\tOther current liabilities\t7\tTotal derivatives not designated as hedges\t1\t7\tTotal derivatives presented gross on the Condensed Consolidated Balance Sheets\t$\t60\t$\t42\tGross amounts not offset on the Condensed Consolidated Balance Sheets:\tDerivative financial instruments\t(\t36\t)\t(\t36\t)\tCash collateral received / pledged\t \t \tNet amount (legal offset)\t$\t25\t$\t7\tThe following table summarizes the effect of our derivative contracts on our Condensed Consolidated Financial Statements:\tThree Months Ended\tMarch 31,\t(in millions)\t2023\t2022\tDerivatives designated as hedges:\tNet gain (loss) recognized in Accumulated other comprehensive income\t$\t(\t6\t)\t$\t28\tNet gain reclassified from Accumulated other comprehensive income into Product sales\t$\t24\t$\t22\tDerivatives not designated as hedges:\tNet gain (loss) recognized in Other income (expense), net\t$\t(\t3\t)\t$\t19\tThe majority of gains and losses related to the hedged forecasted transactions reported in Accumulated other comprehensive income (loss) as of March 31, 2023 are expected to be reclassified to Product sales within\t12\tmonths. There were\tno\tdiscontinuances of cash flow hedges for the three months ended March 31, 2023 and 2022.\tThe cash flow effects of our derivative contracts for the three months ended March 31, 2023 and 2022 were included within Net cash provided by operating activities on our Condensed Consolidated Statements of Cash Flows.\t6.\tACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS\tWe enter into acquisitions, licensing and strategic collaborations and other similar arrangements with third parties for the development and commercialization of certain products and product candidates. The collaborations and other arrangements may involve two or more parties who are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. These arrangements may include non-refundable upfront payments, expense reimbursements or payments by us for options to acquire certain rights, contingent obligations by us for potential development and regulatory milestone payments and/or sales-based milestone payments, royalty payments, revenue or profit-sharing arrangements, cost-sharing arrangements and equity investments.\t16\tAcquisitions\tTmunity\tIn February 2023, we cl"
        ],
        "timestamp": "2025-01-21_09-36-46"
    }
}